Last updated: June 14, 2026
Takeda v. Teva (1:16-cv-00246) patent litigation summary, claims at issue, and generic entry risk
Executive summary: Takeda Pharmaceutical Company Limited v. Teva Pharmaceuticals USA, Inc., 1:16-cv-00246 is a U.S. patent infringement case filed in 2016 in the District of Massachusetts concerning Takeda’s branded product patent rights versus Teva’s proposed generic. The publicly available docket-level record for this case is not sufficient here to provide a complete, accurate, claim-by-claim infringement/invalidity analysis (asserted patent numbers, specific claims, claim constructions, claim charts, settlement terms, and injunction scope).
No litigation summary can be produced that meets a “hard data” standard (patent numbers, asserted claims, holdings, and timelines) for this docket without introducing inaccuracies.
What patents are asserted in Takeda v. Teva 1:16-cv-00246?
A complete litigation analysis requires the asserted U.S. patent numbers and the specific asserted claims listed on the complaint and amended pleadings for 1:16-cv-00246. That information is not present in the provided input, and generating it from memory risks factual error.
What claim types are typically challenged in this docket
For high-stakes Takeda–Teva matters, the dispute usually targets at least one of these:
- Composition/formulation patents (drug substance or solid-state forms)
- Method-of-use patents (therapeutic dosing or regimen)
- Pharmaceutical formulation or manufacturing method patents
A definitive statement on which categories apply to this specific case cannot be made from the current input.
When was Takeda v. Teva 1:16-cv-00246 filed and what are key procedural dates?
A usable timeline requires docket events such as:
- Complaint filing date
- Teva’s answer or counterclaims (infringement/invalidity)
- Claim construction schedule
- Summary judgment dates
- Trial or merits decision date
- Any settlement or dismissal entry
- Appellate docket status (if any)
The current input provides only the case caption and docket number, not the docket timeline.
Why generic entry timing depends on the procedural posture
In Hatch-Waxman disputes, generic launch risk turns on:
- Whether the court entered an injunction
- Whether the asserted patents were found not infringed or invalid
- Whether any patent expired during litigation and whether the case was mooted
Without docket-specific rulings, exclusivity and launch calendars cannot be tied to this case with factual accuracy.
What is the Orange Book status of the Takeda product in 1:16-cv-00246?
To map the litigation to regulatory status, a complete analysis requires:
- The drug product (brand name)
- The listed Orange Book NDA
- The Orange Book patent list tied to the asserted patents
- The expiration dates and any pediatric exclusivity or TRT-related adjustments
None of that identifying information is present in the prompt.
What is the claim construction and legal standard applied in Takeda v. Teva 1:16-cv-00246?
Claim construction results and the court’s interpretation of key claim terms determine:
- Infringement (literal vs. doctrine of equivalents)
- Anticipation/obviousness (prior art mapping to construed elements)
- Enablement/indefiniteness (for invalidity defenses)
A litigation-grade analysis must cite:
- The claim construction order
- The standard for obviousness under 35 USC 103
- The standard for invalidity burdens
No such orders or citations are available in the input.
How strong is Takeda’s patent estate against Teva in this case?
“Strength” in litigation hinges on:
- Surviving asserted claims after motions
- Whether the asserted claims cover the proposed generic product features
- Whether the court found likely infringement or likely invalidity
- Whether prior art references were applied and how
A defensible strength assessment needs the asserted patents, the court’s rulings, and the procedural outcomes.
How does Teva’s Paragraph IV strategy affect the risk of generic entry for this product?
A Paragraph IV challenge analysis requires:
- The ANDA application number
- The certifications for each listed patent (IV, I, II, III, etc.)
- Which patents were challenged under § 271(e)(2)
- Whether Takeda triggered a 30-month stay and whether it expired by:
- court decision dates, or
- settlement/dismissal dates
These items are not provided.
Was there a settlement or dismissal in Takeda v. Teva 1:16-cv-00246, and what did it do to exclusivity?
Settlement analysis requires:
- Settlement agreement terms summary (if publicly available)
- Dismissal with/without prejudice timing
- Whether Teva entered “at risk” or launched on a specific date
- Any negotiated carve-outs (dosage, strength, formulation)
No settlement record is available in the provided input.
What did the court decide in Takeda v. Teva 1:16-cv-00246 (infringement, validity, remedies)?
A proper answer requires the merits outcome such as:
- “infringed” or “not infringed” for each asserted claim
- validity findings (anticipation, obviousness)
- injunctive relief scope and duration
- damages, attorneys’ fees, or enhanced damages (if any)
Those rulings are not available in the prompt.
Key Takeaways
- No litigation-grade summary is possible from the provided input without the docket’s asserted patent list, procedural milestones, and merits or settlement entries.
- Any attempt to provide an “asserted patents and holdings” narrative would risk factual error.
- A complete analysis must start with the complaint and operative pleading patent list and then track the claim construction and merits decisions for 1:16-cv-00246.
FAQs
- What patents were at issue in Takeda v. Teva 1:16-cv-00246?
- Did the court enter an injunction in Takeda v. Teva 1:16-cv-00246?
- Was there a 30-month stay triggered in Takeda v. Teva 1:16-cv-00246, and when did it expire?
- Which claims were construed in Takeda v. Teva 1:16-cv-00246?
- Did the case resolve by trial, summary judgment, or settlement in Takeda v. Teva 1:16-cv-00246?
References (APA)
(No sources were cited because the prompt does not include docket documents or accessible case findings to support an accurate, litigation-grade summary.)
